FDA grants Novartis’ ianalumab breakthrough therapy status for Sjögren’s disease
Novartis intends to submit ianalumab for regulatory approval globally in early 2026.
Drug Development
InterAx and Alveus collaborate on small-molecule metabolic treatment
Agenus and Zydus complete $141m BOT+BAL immunotherapy collaboration deal
Fortress Biotech receives FDA approval for Zycubo to treat Menkes disease
JPM26: SciNeuro and Novartis sign global licensing deal for Alzheimer’s antibody
Atara receives FDA complete response letter for Ebvallo BLA application
MediLink and Roche announce exclusive licensing agreement for YL201
Takeda and Halozyme sign global agreement for Enhanze technology
